Liberum appointed Nomad and Sole Corporate Broker to Futura Medical

Futura Medical is a pharmaceutical company with a pipeline of transdermal delivery products in late stage development. The company’s lead product is MED2005, a topical treatment for erectile dysfunction currently in Phase 3 clinical trial. The company was founded in 1997 and was admitted to trading on AIM in 2003.

Liberum has been appointed as Nomad and Sole Broker with immediate effect.

Liberum Team

Board – David Parsons

Investment Banking – Bidhi Bhoma, Euan Brown, Kane Collings

Research – Graham Doyle, Alistair Campbell

Sales – Lisa Tugwell, Oliver Baxendale, Julian Collett

Corporate and Investor Relations – Natalie Clarke

Twitter: @LiberumToday

LinkedIn: Liberum